Published in AIDS on March 01, 1993
Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev (2002) 2.67
New insights into human cryptosporidiosis. Clin Microbiol Rev (1999) 1.72
Requirement of CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice. Infect Immun (1998) 1.27
Cryptosporidiosis in Wisconsin: a case-control study of post-outbreak transmission. Epidemiol Infect (1996) 1.03
Arginine-derived nitric oxide reduces fecal oocyst shedding in nude mice infected with Cryptosporidium parvum. Infect Immun (1994) 1.03
Role of immunoglobulin A monoclonal antibodies against P23 in controlling murine Cryptosporidium parvum infection. Infect Immun (1998) 0.94
Polymorphic mucin antigens CpMuc4 and CpMuc5 are integral to Cryptosporidium parvum infection in vitro. Eukaryot Cell (2009) 0.93
Balancing the risks and benefits of drinking water disinfection: disability adjusted life-years on the scale. Environ Health Perspect (2000) 0.91
Infection dynamics and clinical features of cryptosporidiosis in SCID mice. Infect Immun (1994) 0.85
Is drinking water a risk factor for endemic cryptosporidiosis? A case-control study in the immunocompetent general population of the San Francisco Bay Area. BMC Public Health (2003) 0.85
Putative anticryptosporidial agents tested with an immunodeficient mouse model. Antimicrob Agents Chemother (1994) 0.83
Efficient capture of pathogens with a zeolite matrix. Parasitol Res (2013) 0.79
Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). Infection (2013) 0.78
Evidence of thymus-independent local and systemic antibody responses to Cryptosporidium parvum infection in nude mice. Infect Immun (1999) 0.77
Cryptosporidiosis in persons with HIV infection. Postgrad Med J (1997) 0.76
Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)). J Virol (2001) 0.76
Cryptosporidiosis in Haiti: surprisingly low level of species diversity revealed by molecular characterization of Cryptosporidium oocysts from surface water and groundwater. Parasite (2013) 0.75
Prevalence of antibodies to human immunodeficiency virus, gonorrhoea rates, and changed sexual behaviour in homosexual men in London. Lancet (1987) 7.71
Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature (1985) 6.65
Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain. Lancet (1984) 5.20
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet (1996) 4.05
Gonorrhoea in homosexual men and media coverage of the acquired immune deficiency syndrome in London 1982-3. Br Med J (Clin Res Ed) (1984) 3.95
Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS (1997) 2.88
Rising prevalence of human T-lymphotropic virus type III (HTLV-III) infection in homosexual men in London. Lancet (1985) 2.72
Hepatitis C virus: evidence for sexual transmission. BMJ (1991) 2.50
Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic. BMJ (1991) 2.49
Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS (1997) 2.20
Attitudes to tracing and notifying contacts of people with HIV infection. BMJ (1992) 2.19
Prophylactic oral acyclovir in recurrent genital herpes. Lancet (1984) 1.99
Human immunodeficiency viruses in patients attending a sexually transmitted disease clinic in London, 1982-7. BMJ (1989) 1.89
Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med (1996) 1.82
The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles. J Med Virol (1982) 1.81
HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet (1995) 1.67
Strongyloides stercoralis infection in renal transplant recipients. Br Med J (Clin Res Ed) (1981) 1.43
Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol (1987) 1.42
Significance of delta agent infection in chronic hepatitis B virus infection: a study in British carriers. Gut (1983) 1.40
Empirical treatment without bronchoscopy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Thorax (1989) 1.32
Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. Br Med J (Clin Res Ed) (1987) 1.28
Lipodystrophy in patients naive to HIV protease inhibitors. AIDS (1999) 1.23
Cytomegalovirus in the lungs of patients with AIDS. Respiratory pathogen or passenger? Am Rev Respir Dis (1990) 1.22
Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic, and MR imaging findings. Radiology (1993) 1.18
Sclerosing cholangitis in acquired immunodeficiency syndrome. Case reports and review of the literature. Scand J Gastroenterol (1988) 1.12
The natural history of human immunodeficiency virus infection: a five year study in a London cohort of homosexual men. Genitourin Med (1990) 1.09
Novel application of a point mutation assay: evidence for transmission of hepatitis B viruses with precore mutations and their detection in infants with fulminant hepatitis B. J Med Virol (1994) 1.05
Clinical and histological features of a group of patients with sporadic non-A, non-B hepatitis. J Clin Pathol (1981) 1.00
The pathology of hepatitis A in man. Liver (1982) 0.99
Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. Gut (1985) 0.98
Reversible zidovudine-induced pure red-cell aplasia. AIDS (1989) 0.97
Acyclovir in hepatitis B antigen-positive chronic liver disease: inhibition of viral replication and transient renal impairment with iv bolus administration. J Antimicrob Chemother (1983) 0.96
ABC of AIDS. Antiretroviral drugs. BMJ (2001) 0.94
Thrice weekly lymphoblastoid interferon is effective in inhibiting hepatitis B virus replication. Liver (1984) 0.93
Acyclovir in first attacks of genital herpes and prevention of recurrences. Genitourin Med (1986) 0.91
Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS (1988) 0.91
Hepatitis B virus infection in patients attending a genitourinary medicine clinic: risk factors and vaccine coverage. Sex Transm Infect (1998) 0.91
Effects of prednisolone/azathioprine in chronic hepatitis B viral infection. Gut (1982) 0.90
Surgical biopsy for persistent generalized lymphadenopathy. Br J Surg (1986) 0.89
Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. Br J Clin Pharmacol (1994) 0.88
A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat (1999) 0.88
Complications of treatment for cryptosporidial diarrhoea. Genitourin Med (1991) 0.87
Human immunodeficiency virus (HIV) infection in the regular sexual partners of homosexual men with AIDS and persistent generalised lymphadenopathy. J Med Virol (1987) 0.87
No effect of zidovudine on hepatitis B virus replication in homosexual men with symptomatic HIV-1 infection. AIDS (1991) 0.87
Spontaneous loss of HBeAg and the prevalence of HTLV-III/LAV infection in a cohort of homosexual hepatitis B virus carriers and the implications for antiviral therapy. J Hepatol (1986) 0.86
From persistent generalised lymphadenopathy to AIDS: who will progress? Br Med J (Clin Res Ed) (1987) 0.86
AIDS: sense not fear. Br Med J (Clin Res Ed) (1984) 0.86
HIV infection alters the production of both type 1 and 2 cytokines but does not induce a polarized type 1 or 2 state. AIDS (1997) 0.86
Subclinical neurological and neuropsychological effect of infection with HIV. Genitourin Med (1989) 0.84
Failure to detect nucleic acid homology between some non-A, non-B viruses and hepatitis B virus DNA. J Med Virol (1983) 0.84
Zidovudine--the first year of experience. J Infect (1989) 0.83
AIDS and the gut. Scand J Gastroenterol Suppl (1985) 0.83
Recognition of poliovirus/HIV chimaeras by antisera from individuals with HIV infection. AIDS (1991) 0.82
The gay bowel. Gut (1985) 0.82
Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy. J Clin Microbiol (1998) 0.82
Serial MRI of the brain in asymptomatic patients infected with HIV: results from the UCMSM/Medical Research Council neurology cohort. J Neurol Neurosurg Psychiatry (1994) 0.81
Rapid detection of immunoreactive interferon-alpha in AIDS. Lancet (1984) 0.81
Randomised placebo controlled trials in HIV infection: to be or not to be? Genitourin Med (1989) 0.80
Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine. AIDS (1990) 0.80
Shared care in HIV and AIDS: shifting care or shifting costs? J R Coll Physicians Lond (1998) 0.80
Acyclovir inhibits hepatitis B virus replication in man. Lancet (1982) 0.80
Conservation of precore and core sequences of hepatitis B virus in chronic viral carriers. J Med Virol (1994) 0.80
Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine. J Neurol (1993) 0.79
HIV, glue ear, and adenoidal hypertrophy. Lancet (1988) 0.79
Proton Spectroscopy in a Cross-Section of HIV-Positive Asymptomatic Patients Receiving Immediate Compared with Deferred Zidovudine (Concorde Study). J NeuroAIDS (1997) 0.78
Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis (1996) 0.78
Failure to demonstrate anti-lymphocytic antibody in serum of patients with AIDS. AIDS (1987) 0.78
Thalidomide hypersensitivity in AIDS. Lancet (1991) 0.78
Clinical, biochemical, serological, histological and ultrastructural features of liver disease in drug abusers. Gut (1984) 0.78
ABC of AIDS: Treatment of infections. BMJ (2001) 0.77
Human immunodeficiency virus (HIV) infection for the general physician. Postgrad Med J (1987) 0.75
Disseminated cytomegalovirus infection. Genitourin Med (1992) 0.75
Safety, tolerance, and efficacy of atevirdine in asymptomatic human immunodeficiency virus-infected individuals. Antimicrob Agents Chemother (1996) 0.75
A pilot study of BW A515U (6-deoxyacyclovir) in chronic hepatitis B virus infection. J Hepatol (1986) 0.75
Inhibition of hepatitis B viral replication by lymphoblastoid interferon. Philos Trans R Soc Lond B Biol Sci (1982) 0.75
Hepatitis B: reactivation or reinfection associated with HIV-1 infection. Lancet (1989) 0.75
Immune neutropenia in homosexual men. Lancet (1985) 0.75
Clinical trials in HIV infection: current problems and future directions. AIDS (1991) 0.75
A randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection. J Hepatol (1986) 0.75
Lack of suppression by ribavirin of HIV viraemia. Lancet (1992) 0.75
ABC of AIDS. Gastrointestinal and hepatic manifestations. Br Med J (Clin Res Ed) (1987) 0.75
Treatment of chronic hepatitis B virus infection. Clin Exp Obstet Gynecol (1983) 0.75